When evaluating surveys that discussed the use of medical cannabis products for dermatologic conditions, researchers found that consumers are interested in and currently using these products.
Indena Authorized to Produce CBD-based Extracts March 8, 2021 Contact Author Michele Behrens
Close
Indena started to produced pharmaceutical-grade CBD for the international market.
Sponsored
Indena has been authorized by the Italian Ministry of Health and Italian Medicines Agency (AIFA) to produce cannabinoid-based cannabis extracts.
Indena will produce pharmaceutical-grade cannabidiol (CBD) for the global market for clinical and commercial use. It is reportedly the first company in Italy to receive authorization from the Ministry of Health to manufacture cannabinoid-based cannabis extracts.
The supply chain, which complies with the criteria set out in the Italian regulations, is controlled, certified and fully traced by the company. Indena uses registered varieties of hemp with a THC level of less than 0.2%, in accordance with European standards. It also guarantees a residual THC content of less than 0.02%, which is well below the limits defined by the U.S.